Cancer Diagnostics
Total Trials
3
As Lead Sponsor
0
As Collaborator
Total Enrollment
328
NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase: Phase 2
Role: Collaborator
Start: Jun 18, 2024
Completion: Aug 24, 2031
NCT06693830
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Phase: N/A
Start: Dec 11, 2024
Completion: Dec 31, 2029
NCT07021989
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Start: Oct 31, 2025
Completion: Apr 30, 2033
Loading map...